Xeris Biopharma Holdings, Inc. (XERS)
NMS – Real vaqt narxi. Valyuta: USD
8.44
+0.04 (0.54%)
Bozor ochiq: Aug 12, 2026, 11:55 AM EDT
8.27
-0.12 (-1.43%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Find any stock by ticker or company name

NMS – Real vaqt narxi. Valyuta: USD
8.44
+0.04 (0.54%)
Bozor ochiq: Aug 12, 2026, 11:55 AM EDT
8.27
-0.12 (-1.43%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Xeris Biopharma Holdings, Inc., tijorat bosqichidagi biofarmatsevtika kompaniyasi, Illinoys shtatida surunkali endokrin va nevrologik kasalliklar uchun davolash usullarini ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. U bolalar va kattalar bemorlarda og'ir gipoglikemiyani davolash uchun tayyor suyuq glyukagon Gvoke; giperkaliemik, gipokaliemik va birlamchi davriy falajning tegishli variantlarini davolash uchun Keveyis terapiyasi; va Kushing sindromi bilan og'rigan kattalar bemorlarda endogen giperkortizolizmni davolash uchun kortizol sintezi ingibitori Recorlevni taklif etadi. Kompaniya, shuningdek, gipoteriozni davolash uchun 3-bosqichli klinik sinovda bo'lgan haftasiga bir marta teri ostiga yuboriladigan levotiroksin XP-8121ni ishlab chiqmoqda. Kompaniya 2005 yilda tashkil etilgan va shtab-kvartirasi Illinoys shtatining Chikago shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Anh T. Nguyen M.B.A., M.D. | Chief Medical Officer |
| Mr. Brian Conner | SVP of Quality and Chief Compliance & Risk Officer |
| Mr. John P. Shannon | Chairman & CEO |
| Mr. Kevin McCulloch | President & COO |
| Mr. Steven M. Pieper | Chief Financial Officer |
| Ms. Allison Wey | Senior Vice President of Investor Relations & Corporate Communications |
| Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Kendal Korte | Senior Vice President of Human Resources |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-06 | 8-K | xers-20260806.htm |
| 2026-07-17 | 8-K | xers-20260715.htm |
| 2026-06-30 | 8-K | xers-20260629.htm |
| 2026-06-11 | 8-K | xers-20260610.htm |
| 2026-06-05 | 8-K | xers-20260604.htm |
| 2026-05-07 | 8-K | xers-20260507.htm |
| 2026-05-07 | 10-Q | xers-20260331.htm |
| 2026-04-23 | DEF 14A | xers-20260423.htm |
| 2026-04-23 | ARS | xers2025annualreport.pdf |
| 2026-04-21 | 8-K | xers-20260420.htm |